Financings in Brief: Perkin-Elmer/Tecan AG
This article was originally published in The Gray Sheet
Perkin-Elmer/Tecan AG: Integrated life science systems firm Perkin-Elmer plans to acquire 14.5% of Swiss firm Tecan AG under a definitive agreement, giving Perkin-Elmer 52% of the voting rights in Tecan. The firms "contemplate an expanded program to automate molecular biology and pharmaceutical processes designed to accelerate drug discovery, development and testing," Perkin-Elmer states in a release. The agreement with Tecan, "given their expertise in robotics and system automation, enhances our ability to fulfill our vision of providing automated and integrated high-throughput discovery systems that define the molecular medicine paradigm," states Tony White, Perkin-Elmer chairman, president and CEO. Specific terms of the cash deal are not being disclosed...
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.